Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017: Market Insights, Emerging Therapies, and Market Forecast till 2022

Albany, New York, October 9, 2017: Presented study, Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request Free Sample Report@  https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1339576

Cathepsin S (CTSS or EC 3.4.22.27)-Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils. The molecules developed by companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 1, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Infectious Disease, Metabolic Disorders and Musculoskeletal Disorders which include indications Neuropathic Pain, Rheumatoid Arthritis, Alzheimer’s Disease, Autoimmune Disorders, Cancer Pain, Celiac Disease, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Crohn’s Disease (Regional Enteritis), Diabetic Retinopathy, Liver Fibrosis, Lupus Nephritis, Osteoarthritis, Pancreatic Cancer, Primary Biliary Cirrhosis, Sicca Syndrome (Sjogren) and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/cathepsin-s-ctss-or-ec-342227-pipeline-review-h2-2017-report.html

Scope

– The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
– The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
– The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Enquire About this Report@ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1339576

 

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: – 800-998-4852 (US-Canada)
Email:- press@marketresearchhub.com
Website:- https://www.marketresearchhub.com/
Read Industry News at :- https://www.industrynewsanalysis.com/

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net